1.
ACS Med Chem Lett
; 2(10): 715-9, 2011 Oct 13.
Article
in English
| MEDLINE
| ID: mdl-24900257
ABSTRACT
A novel series of HCV replication inhibitors based on a pyrido[3,2-d]pyrimidine core were optimized for pharmacokinetics (PK) in rats. Several associations between physicochemical properties and PK were identified and exploited to guide the design of compounds. In addition, a simple new metric that may aid in the prediction of bioavailability for compounds with higher polar surface area is described (3*HBD-cLogP).